Dr. Dowling’s Biography:
Ryan received his PhD from McGill University in 2009 and joined the Princess Margaret Cancer Centre (PMCC) shortly thereafter. He spent 10 years at PMCC, first as a postdoctoral fellow and later as an affiliate scientist, studying the impact of obesity and insulin on cancer development and progression, as well as the clinical use of metformin as a potential anti-cancer therapy. He was also an instructor in the Department of Medical Biophysics.
In 2020, Ryan accepted a position at Hoffmann-La Roche as a Global Clinical Project Manager where he has worked extensively with the clinical development teams to develop and amend protocols and patient consent forms for many pivotal clinical trials in a variety of therapeutic areas including oncology, hematology, neurology, and COVID-19. As part of the Product Development Regulatory Documentation department, Ryan serves as the Business Process Owner for both protocols and consent forms, overseeing the proper management and evolution of these critical regulatory documents.
Sign up here: https://forms.gle/bhRWMffvncR9YAxXA